Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

in the effort to create a vaccine. Will their partnership lead to a new model for drug development that accelerates medical innovation? Here’s Afeyan again: ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Moderna's stock fell more ... of Novavax and GSK both fell around 1%. Pfizer's stock fell almost 2%, even after the company ...

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...